12:00 AM
 | 
Mar 19, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 3/16 cls
Anthera Pharmaceuticals Inc. (NASDAQ:ANTH) Cowen Steve Scala Downgrade Neutral (from outperform) -51% $3.17
Deutsche Bank Navdeep Singh Price target Buy
Piper Jaffray Edward Tenthoff Price target Overweight
Summer Street Carol Werther Price target Buy
Wedbush Duane Nash Price target Outperform
Scala downgraded after Anthera said it would discontinue development of cardiovascular compound varespladib for all indications after it showed a lack of efficacy in the Phase III VISTA-16 trial to treat acute coronary syndrome (ACS). Anthera made the decision based on...

Read the full 888 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >